We also compared several clinical parameters; i.e., age at CLL diagnosis, DLBCL subtype, and the number of CLL therapy cycles received, but did not find significant differences between CARD9-positive and -negative cases in this small cohort (Supplementary Table S2). This evidence concerns the gene CARD9 and diffuse large B-cell lymphoma.